欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
应用第2代测序技术对大系列骨髓增生异常综合征（MDS）患者的研究初步揭示了MDS发病的分子基础.约90％的MDS患者至少存在≥1个基因突变,最常受累基因有SF3B1、TET2、SRSF2、ASXL1、DNMT3A和RUNX1.随着MDS克隆演变和受累基因功能研究的深入,有望进一步完善MDS患者的预后判断和治疗方案的制定.
英文摘要：
The molecular basis of myelodysplastic syndromes （MDS） is revealed by whole genome sequencing or targeted gene sequencing in several large cohort of patients with MDS.About 90 ％ of MDS patients carry ≥ 1 oncogenic mutations,the consistently mutated genes are SF3B1,TET2,SRSF2,ASXL1,DNMT3A and RUNX1.The further studies of clonal architecture of MDS and the functions of the involved genes might considerably improve prognostication of MDS and more generally clinical decision-making in this field.
同期刊论文项目
同项目期刊论文
RAD51 and XRCC3 polymorphisms: Impact on the risk and treatment outcomes of de novo inv(16) or t(16;
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentia
Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring siderobla
~JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferati
Serum Ferritin Is an Independent Prognostic Factor in Chinese with Myelodysplastic Syndromes Classif
Polymorphisms in folate-related genes: impact on risk of adult acute lymphoblastic leukemia rather t
期刊信息
位置：